Advertisement
Screener

Odyssey Therapeutics, Inc. (ODTX) Revenue

Odyssey Therapeutics, Inc. Revenue

Odyssey Therapeutics, Inc. (ODTX) reported Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06

  • Odyssey Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
  • Odyssey Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
  • Odyssey Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $959.00K.
  • Odyssey Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $1.92M.
Period endRevenue from Contract with Customer, Excluding Assessed Tax 3 monthRevenue from Contract with Customer, Excluding Assessed Tax 6 month
2026-06-30$0.00
10-Q · filed 2026-08-06
$0.00
10-Q · filed 2026-08-06
2026-03-31$0.00
10-Q · filed 2026-06-17
2025-06-30$959.00K
10-Q · filed 2026-08-06
$2.88M
10-Q · filed 2026-08-06
2025-03-31$1.92M
10-Q · filed 2026-06-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Vor Biopharma Inc. (VOR)United States$1.091B1.60
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
Replimune Group, Inc. (REPL)United States$1.186B-3.13
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10